{"filings":[{"id":1258717,"accession_number":"0001628280-26-045350","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-06-25T11:10:14+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints Carolyn Starrett, former Flatiron Health CEO, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 directors; Starrett fills new seat effective June 23, 2026.","Starrett brings 25+ years experience in data/tech, AI, and cancer care; was CEO of Flatiron Health from 2021-2025.","She will serve until 2027 annual meeting; compensation per standard director program.","Chair Lynn Tetrault cites Starrett's expertise in real-world data and analytics for cancer care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1197276,"accession_number":"0001077183-26-000037","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-06-22T21:17:36+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"NeoGenomics issues $316.25M of 0.75% convertible notes due 2032, repurchases $276M of existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $316.25M aggregate principal of 0.75% Convertible Senior Notes due 2032, conversion price ~$14.16 (35% premium to $10.49 close).","Used ~$28.7M of proceeds for capped call transactions (cap $20.98/share) to reduce potential dilution upon conversion.","Repurchased ~$276M principal of existing 0.25% notes due 2028 for ~$263.19M cash, extending debt maturity.","Repurchased up to $25M of common stock at $10.49/share in private transactions with certain note purchasers.","New notes mature July 1, 2032; interest paid semiannually at 0.75% starting Jan 1, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1092596,"accession_number":"0001077183-26-000031","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-06-17T10:05:23+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeoGenomics prices $275M convertible notes due 2032; to repurchase $276M of existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$275M principal of 0.75% convertible notes due 2032; initial purchasers have option for additional $41.25M.","Initial conversion price ~$14.16/share, a 35% premium to $10.49 closing price on June 16, 2026.","Net proceeds ~$266.15M; ~$25M used for capped call transactions (cap price $20.98/share).","Concurrently repurchasing $276M of existing 0.25% convertible notes due 2028 for ~$263.19M.","Also plans to repurchase up to $25M of common stock from certain note purchasers; offering expected to close June 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1059118,"accession_number":"0001077183-26-000029","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-06-15T21:24:55+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeoGenomics commences $275M convertible note offering due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering $275M aggregate principal amount of convertible senior notes due 2032, with option for additional $41.25M.","Notes offered to qualified institutional buyers under Rule 144A; interest rate and conversion rate set at pricing.","Proceeds used to repurchase a portion of existing 0.25% convertible notes due 2028 and up to $25M of common stock.","Company to enter capped call transactions to reduce potential dilution upon conversion.","The offering is contingent on market conditions and not registered under the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609919,"accession_number":"0001628280-26-037735","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-05-22T20:19:44+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NeoGenomics stockholders approve 5M share increase to 2023 equity plan, elect all director nominees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; Lynn Tetrault received 105.7M votes for (96.9% of votes cast).","Advisory say-on-pay passed with 83.19% of votes cast in favor.","Amendment to 2023 equity plan increasing authorized shares by 5,000,000 approved with 97.9% of votes cast.","Ratification of Deloitte as independent auditor approved with 99.57% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91128,"accession_number":"0001077183-26-000022","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.","Net loss narrowed 34% to $17M; adjusted EBITDA $9M (+27% YoY).","Raised FY2026 revenue guidance to $797-803M (prior range not specified).","Launched RaDaR ST MRD assay; received MolDX coverage for PanTracer LBx.","Cash and marketable securities $146M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":186672000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101047,"accession_number":"0001077183-26-000004","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q4 revenue up 11% to $190M; full-year net loss widens to $108M; RaDaR ST MRD launch imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.","Q4 net loss decreased 36% to $10M; full-year net loss increased 37% to $108M; Adjusted EBITDA positive $13M (Q4) and $43M (FY).","Clinical NGS volumes grew 23% in Q4 and 22% for full year, outpacing market growth.","RaDaR ST MRD assay imminent clinical launch; company addresses $20B+ MRD monitoring market; modest 2026 revenue expected.","Successfully resolved RaDaR ST patent litigation (no financial details disclosed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":727332000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101046,"accession_number":"0001628280-26-001746","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"NeoGenomics prelim Q4 rev $190M (+11% YoY), FY rev $727M (+10%); CFO Sherman retiring, Jain appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2025 revenue ~$190M (+11% YoY); full-year 2025 revenue ~$727M (+10% YoY).","CFO Jeff Sherman to retire; will become EVP Finance on March 2, 2026, then special adviser through April 2028.","Abhishek Jain joins as EVP Finance Jan 12, 2026; to assume CFO role on March 2, 2026.","Jain's compensation: base salary $520K, target bonus 60% of salary, initial equity grant $2.75M (RSUs and options).","Results are preliminary and subject to change; final results expected in February 2026 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117393,"accession_number":"0001628280-25-059067","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints Jack Kenny to board; Dr. Alison Hannah departs after 10 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Alison Hannah resigns from NeoGenomics board effective Dec 31, 2025, after over 10 years of service.","Jack Kenny appointed to board effective Jan 1, 2026; former CEO of Meridian Bioscience (taken private 2023).","Mr. Kenny brings 30+ years of diagnostics and lab services experience; also serves on Orasure, DCN, Quantum-SI boards.","Mr. Kenny's compensation is consistent with NeoGenomics' director compensation plan as disclosed in 2025 proxy.","No related-party transactions involving Mr. Kenny requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117392,"accession_number":"0001077183-25-000172","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.","Net loss $27M vs $18M, up 53%; adjusted EBITDA $12.2M, down 9% from $13.4M.","Reaffirmed FY 2025 guidance: revenue $720-726M, net loss $(116)-(108)M, adj EBITDA $41-44M.","OpEx +12% YoY, includes $7.1M impairment charge on Trapelo held-for-sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":537162000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133811,"accession_number":"0001077183-25-000162","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Elizabeth Floegel resigns from NeoGenomics Board effective August 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth Floegel resigned from the Board of Directors effective August 5, 2025.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement has been announced; Board size reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133810,"accession_number":"0001077183-25-000151","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).","Net loss widened 142% to $45M including $20M impairment charges.","Adjusted EBITDA flat at $10.7M vs $10.9M last year.","Full-year 2025 revenue guidance cut to $720-$726M (prev $747-$759M); Adj EBITDA guidance lowered to $41-$44M.","Acquired Pathline for $8M cash plus $1M contingent consideration in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":349365000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150544,"accession_number":"0001077183-25-000145","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints Merck oncology head Dr. Marjorie Green to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marjorie C. Green appointed to NeoGenomics board effective June 19, 2025; board expands from 9 to 10 members.","Dr. Green is SVP and Head of Oncology, Global Clinical Development at Merck, leading oncology R&D for Merck's largest revenue area.","Prior leadership roles include SVP Late-Stage Development at Seagen and VP at Genentech; began career as medical oncologist at MD Anderson.","She will serve as an independent director until the 2026 annual meeting; compensation follows standard director program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150543,"accession_number":"0001077183-25-000109","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NeoGenomics shareholders approve 4.325M share increase to 2023 Equity Plan, all directors re-elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2023 Equity Incentive Plan approved: +4.325M shares, 1-year minimum vesting, no liberal share recycling.","All nine director nominees elected; votes ranged from 93.7% to 99.1% support (excluding broker non-votes).","Advisory say-on-pay passed with 81.77% of votes cast; board adopted annual frequency for future votes.","Ratification of Deloitte & Touche as auditor received 99.86% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150542,"accession_number":"0001077183-25-000074","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q1 revenue up 8% to $168M; adjusted EBITDA turns positive at $7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $168M (+8% YoY); net loss improved 4% to $26M.","Adjusted EBITDA $7M vs $3M prior year, up 102%.","Revenue per clinical test $459 (+3%).","Revised FY2025 guidance: revenue $747-759M, adj. EBITDA $55-58M.","Pathline acquisition adds $12-14M expected revenue to 2025 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":168035000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150541,"accession_number":"0001077183-25-000067","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"NeoGenomics amends bylaws to tighten advance notice rules for stockholder director nominations","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholder nominations must be received 90-120 days before anniversary of prior annual meeting.","Nominations must include stockholder info, proxy solicitation intent, and nominee details per Exchange Act.","Stockholders must comply with Rule 14a-19 universal proxy rules.","Amendment approved by Board on April 4, 2025, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169504,"accession_number":"0001077183-25-000055","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K/A","filed_at":"2025-03-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics finalizes CEO Zook employment agreement: $850K salary, 100% bonus target, $8M equity","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $850,000 per year, effective April 1, 2025, subject to Board adjustment.","Target annual bonus of 100% of base salary, based on performance metrics set by Board/Committee.","Initial equity award target value of $8M, split evenly between restricted stock and premium-priced stock options.","Eligible for annual equity awards with $8M target value starting fiscal 2026, subject to approval.","Severance: 1x salary + 1x target bonus for non-CIC termination; 2x salary + 1x target bonus for CIC termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169503,"accession_number":"0001077183-25-000052","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K/A","filed_at":"2025-03-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics promotes Warren Stone to President & COO; Melody Harris to depart","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warren Stone promoted to President & COO effective April 1, 2025; previously CCO.","Stone's base salary increased to $650k, target bonus 70%, equity target $3M, plus incremental $1M equity.","Melody Harris to depart end of May 2025; her role as COO and President, Oncology Data Solutions eliminated.","Beth Eastland, SVP Enterprise Sales, to support Stone and assume day-to-day enterprise sales functions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169508,"accession_number":"0001077183-25-000048","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics promotes Warren Stone to President & COO; COO Melody Harris to depart in May","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warren Stone promoted from CCO to President & COO effective April 1, 2025; retains commercial duties and adds lab operations, data solutions, enterprise operations.","Melody Harris, current COO, will depart at end of May 2025; the COO position is eliminated.","Stone's base salary raised to $650,000, target bonus 70% of salary, annual equity target $3M; receives incremental $1M equity grant on April 1.","Incoming CEO Tony Zook says alignment of commercial and operations teams increases agility and supports growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169507,"accession_number":"0001077183-25-000024","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q4 revenue +11% to $172M; FY24 $661M; guides FY25 rev $735-745M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 consolidated revenue $172M (up 11% YoY); net loss $15M vs $14M in Q4 2023.","FY24 consolidated revenue $661M (+12% YoY); net loss $79M (improved from $88M).","Adjusted EBITDA FY24 positive $40M vs $3M in 2023, a 1,036% increase.","FY2025 guidance: revenue $735-745M (11-13% growth); adjusted EBITDA $55-58M.","Ninth consecutive quarter of double-digit revenue growth; NGS grew 34% in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":660566000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169506,"accession_number":"0001077183-25-000007","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics guides 2025 revenue $735-745M, adj. EBITDA $55-58M; issues retention bonuses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 revenue guidance $735-745M (midpoint $740M) vs FY24 $661M, ~12% YoY growth.","2025 adjusted EBITDA guidance $55-58M vs FY24 $38.5M, up 43-51%.","Long-range plan: 12-13% annual revenue growth; NGS growth ~25% per year.","Retention bonuses: CFO Sherman ($400K cash + $750K RSUs), Presidents Harris and Stone each similar with vesting thru 2026.","Expects to retire 2025 convertible notes due May 1 with cash on hand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169505,"accession_number":"0001077183-25-000005","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics CEO Chris Smith to retire April 1; board member Tony Zook named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Smith retires as CEO effective April 1, 2025; will serve as special advisor through Feb 2027 at $23,913/month.","Tony Zook, independent board member since June 2023, appointed CEO effective April 1; base salary $850k with 100% target bonus and ~$8M annual equity target.","Smith's retirement package includes pro-rated 2025 bonus, accelerated vesting of 265,452 restricted shares, and 12-month option exercise extension.","Company reaffirms FY2024 guidance: revenue $655–$667M, net loss $(81)–$(78)M, adjusted EBITDA $37–$40M.","NeoGenomics reported eight consecutive quarters of double-digit revenue growth under Smith's tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186555,"accession_number":"0001077183-24-000153","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"NeoGenomics Q3 revenue up 10% to $168M; adjusted EBITDA up 305%, raises FY guidance to $37-40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $168M (+10% YoY); Clinical Services revenue $146M (+14%) with test volume +9%.","Net loss decreased 4% to $18M; adjusted EBITDA improved 305% to $13M, fifth consecutive positive quarter.","FY 2024 adjusted EBITDA guidance raised to $37-40M (from $33-37M); revenue guidance unchanged at $655-667M.","Board appointed Felicia Williams; initial equity award ~$140,000 vesting June 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":488566000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203131,"accession_number":"0001077183-24-000106","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q2 revenue $165M (+12% YoY); raises FY2024 EBITDA guidance to $33-37M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $165M (+12% YoY); net loss narrowed 23% to $19M.","Adjusted EBITDA $11M (+630% YoY) vs -$2M in prior-year quarter.","Clinical Services revenue $141M (+15% YoY); Advanced Diagnostics $23M (-3%).","FY2024 guidance raised: revenue $655-667M (from $650-660M); adj. EBITDA $33-37M (from $21-24M).","Cash and marketable securities $388M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":320742000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219431,"accession_number":"0001077183-24-000081","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeoGenomics annual meeting elects all 9 directors, passes say-on-pay with 69.5% support","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["117.6M shares (92.1% of outstanding) voted at May 23, 2024 annual meeting.","All 9 director nominees elected; Lynn Tetrault and Michael Kelly each received >25M withhold votes.","Advisory say-on-pay vote passed with 69.5% for, 30.5% against.","ESPP amendment approved with 99.8% of votes cast.","Ratification of Deloitte as auditor approved with 99.7% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219430,"accession_number":"0001077183-24-000052","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q1 revenue up 14% to $156M; Adjusted EBITDA turns positive at $3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Clinical Services revenue rose 17% to $135M; test volume up 5% YoY, revenue per test up 11% to $447.","Advanced Diagnostics revenue declined 3% to $22M; consolidated net loss narrowed 12% to $27M.","Adjusted EBITDA was $3M, a $10M improvement from -$7M in Q1 2023; cash and equivalents at $385M.","FY 2024 guidance reaffirmed: revenue $650M-$660M (10-12% growth), Adjusted EBITDA $21M-$24M.","CEO Chris Smith cited solid execution, NGS adoption growth, and consecutive revenue-per-test improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":156240000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219429,"accession_number":"0001077183-24-000048","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeoGenomics eliminates President, Advanced Diagnostics role; promotes Harris and Stone","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vishal Sikri steps down as President, Advanced Diagnostics; role eliminated in restructuring.","Melody Harris becomes Chief Operations Officer and President, Informatics (previously President, Enterprise Operations).","Warren Stone becomes Chief Commercial Officer (previously President, Clinical Services).","Effective date of Sikri's departure not yet determined; ongoing restructuring efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239263,"accession_number":"0001077183-24-000019","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K/A","filed_at":"2024-02-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics files 8-K/A solely to add Cover Page XBRL tagging; no change to prior disclosure","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to Feb 23, 2024 8-K adds Inline XBRL tagging on cover page only.","No new financial or operational information provided; prior Item 5.02 PSU form adoption unchanged.","Original event was adoption of performance-based RSU award form under 2023 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239265,"accession_number":"0001077183-24-000016","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics adopts new performance-based RSU award agreement form","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Culture & Compensation Committee authorized new form of PSU agreement under 2023 Equity Incentive Plan on Feb 16, 2024.","PSUs vest based on Stock Price Growth (20-day trailing average price) and 3-Year Cumulative Revenue goals.","Form filed as Exhibit 10.1; all specific metrics, dates, and participant names remain placeholder brackets.","No individual grants or changes to executive compensation disclosed; purely a template adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239264,"accession_number":"0001077183-24-000009","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q4 revenue $156M (+12% YoY); FY loss narrows 39% to $88M; guides FY24 rev $650-660M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 consolidated revenue $156M (+12% YoY); Clinical Services +20% to $130M, Advanced Diagnostics -17% to $25M.","Q4 net loss $14M (improved from $23M loss in Q4'22); Adjusted EBITDA turned positive to $9M (vs -$1M).","Full year revenue $592M (+16% YoY); net loss $88M (improved from $144M); Adjusted EBITDA positive $3M (vs -$48M).","FY2024 guidance: revenue $650-660M (10-12% growth), net loss $(72)-$66M, Adjusted EBITDA $21-24M (600-700% improvement).","Cash and marketable securities $415M at year-end; no debt or dividend changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":591643000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256772,"accession_number":"0001077183-23-000136","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q3 revenue up 18% to $152M, net loss halved, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $152M (+18% YoY); Clinical Services $128M (+20%), Advanced Diagnostics $24M (+8%).","Net loss decreased 50% to $19M; Adjusted EBITDA turned positive at $3M vs -$12M YoY.","Raised FY23 revenue guidance to $585-592M (15-16% growth); Adj. EBITDA loss guidance improved to $4M-$1M loss.","Cash and marketable securities $402M at quarter end.","Adjusted Gross Profit Margin 44.2%, excluding amortization of acquired Inivata developed technology intangibles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":436091000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274128,"accession_number":"0001077183-23-000099","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q2 revenue up 18% to $147M; net loss narrows 31% to $24M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $147M (+18% YoY); Clinical Services $123M (+17%), Advanced Diagnostics $24M (+22%).","Net loss decreased 31% to $24M; Adjusted EBITDA improved 87% to -$2M from -$16M.","Adjusted Net Loss $7M vs $20M in prior year; cash and marketable securities $409M.","FY 2023 guidance raised: revenue $565-575M, net loss $(107)-(100)M, Adjusted EBITDA $(13)-(10)M.","Pharma Services segment rebranded as Advanced Diagnostics; restructuring charges included in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":284137000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291317,"accession_number":"0001077183-23-000080","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints three independent directors to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rachel Stahler resigned from the Board effective June 26, 2023; no disagreement with company.","Elizabeth Floegel (Numotion CIO), Neil Gunn (ex-IDbyDNA CEO), and Tony Zook (ex-Innocoll CEO) appointed.","Floegel joins Audit & Finance and Compliance Committees; Gunn joins Culture & Compensation and Nominating Committees.","Zook joins Audit & Finance and Culture & Compensation Committees. Board expanded from 8 to 10 members.","Appointments effective June 29, 2023; directors serve until 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291316,"accession_number":"0001077183-23-000068","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeoGenomics annual meeting: all directors elected; say-on-pay passes with 51.79% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight directors elected with votes For ranging from 97.2M (Kelly) to 105.7M (Smith).","Advisory say-on-pay passed narrowly: 51.79% For, 45.37% Against, 2.84% Abstain.","2023 Equity Incentive Plan approved by 95.28% of votes cast (100.8M For).","Ratification of independent auditor approved with 99.82% (113.2M For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291315,"accession_number":"0001077183-23-000057","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics adopts new PSU award form, grants $250K relocation to President Harris","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["New form of performance-based RSU agreement ties vesting to absolute total shareholder return (stock price targets).","PSU awards vest only if grantee remains employed through vesting date; forfeited on separation except death/disability/change in control.","Amendment provides Melody Harris $250,000 relocation benefit when she moves to Southwest Florida; all other employment terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291314,"accession_number":"0001077183-23-000039","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q1 revenue up 17% to $137M; narrows net loss; raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $137M (+17% YoY); Clinical +16% to $115M, Pharma +22% to $22M.","Net loss improved to $31M from $49M; Adjusted EBITDA loss narrowed to $7M from $19M.","FY2023 revenue guidance raised to $555-$565M from $545-$555M; Adj. EBITDA loss guidance improved to $(22)-$(18)M.","Cash and marketable securities $418M; adjusted gross profit margin 43.5%.","Clinical test volume +7% YoY; revenue per test +8% to $402."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":137220000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291313,"accession_number":"0001077183-23-000028","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeoGenomics posts investor presentation; full content not provided in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1 to the 8-K.","Presentation covers company overview, strategy, and financial outlook.","No specific financial metrics or guidance changes disclosed in the excerpt provided.","Filing made under Regulation FD; information is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312105,"accession_number":"0001077183-23-000019","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q4 revenue up 10% to $139M; net loss narrows to $23M; issues 2023 guidance with improved EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $139M (+10% YoY); full year revenue $510M (+5% YoY).","Q4 net loss $23M vs $42M loss in Q4 2021; full year net loss $144M vs $8M loss in 2021 (2021 included $109M Inivata gain).","Q4 adjusted EBITDA -$1.2M vs -$10M in Q4 2021; full year adjusted EBITDA -$48M vs -$4M in 2021.","2023 guidance: revenue $545-555M (7-9% growth), adjusted EBITDA $(27)-$(22)M (44-54% improvement).","Cash and marketable securities $438M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":509728000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312104,"accession_number":"0001077183-23-000008","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director David J. Daly resigns from NeoGenomics Board effective Jan 19, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Daly resigned from the Board immediately; no reason other than not due to disagreement.","Resignation not related to any disagreement on operations, policies, or practices.","No replacement director has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330683,"accession_number":"0001077183-22-000197","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints Jeffrey S. Sherman as CFO; William Bonello steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey S. Sherman named CFO effective Dec 7, 2022; William Bonello remains as employee for transition support.","Base salary $525,000; annual target bonus 70% of salary; sign-on cash $250,000; sign-on equity $3,000,000 (RSUs and options).","Sherman has 32 years healthcare finance experience, previously CFO at Privia Health, HMS, AccentCare, Lifepoint Hospitals.","Sherman led the sale of HMS to Veritas-backed Gainwell Technologies for $3.4 billion in April 2021.","CEO Chris Smith highlights Sherman's skills in pricing, revenue cycle management to return NeoGenomics to profitable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330682,"accession_number":"0001077183-22-000176","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeoGenomics appoints Melody Harris as President, Enterprise Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melody Harris, age 56, appointed as President, Enterprise Operations effective Dec 5, 2022.","Previously President and COO of SomaLogic, a diagnostics company.","Base salary of $525,000/year; annual cash bonus target 50% of salary; annual equity award of $1M; sign-on equity grant of $2M.","Severance: 1x salary+bonus if terminated without cause; 2x salary+1x bonus if termination within change of control period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330681,"accession_number":"0001077183-22-000169","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q3 revenue $129M (+6%); net loss widens to $37M, adjusted EBITDA -$12M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $129M (+6% YoY); Clinical Services $106M (+4%), Pharma Services $23M (+18%).","Test volume -1% YoY; revenue per test +5% to $392.","Net loss $37M (vs $20M loss in Q3 2021); prior year included $18M gain on Inivata investment.","Adjusted EBITDA -$12M (vs -$3M); Adjusted Net Loss -$18M (vs -$10M).","Cash and marketable securities $444M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":371023000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330680,"accession_number":"0001077183-22-000163","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeoGenomics appoints David Perez to board, Warren Stone as clinical services president","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David B. Perez appointed to Board effective Nov 3, 2022; term until 2023 annual meeting.","Warren Stone appointed President, Clinical Services Division effective Nov 21, 2022, replacing Dr. David Sholehvar.","Stone's compensation: $525K base, 50% target bonus, $1M annual equity, $350K sign-on cash, $2M sign-on equity, $250K relocation.","Perez is former Terumo BCT CEO; brings 40 years of global executive leadership experience in medical devices and healthcare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330679,"accession_number":"0001077183-22-000153","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeoGenomics grants retention agreement to CAO Cynthia Dieter worth $250K","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Cash retention bonus of $150,000, payable 50% on Mar 31, 2023 and 50% on May 31, 2023, subject to continued employment.","Restricted stock award of $100,000, vesting ratably on Nov 1 of 2023–2026, subject to continued employment.","Agreement approved by Culture and Compensation Committee on October 15, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348183,"accession_number":"0001077183-22-000140","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeoGenomics amends CEO employment agreement with $3.35M restricted stock inducement and $800K relocation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendment provides incoming CEO Christopher Smith restricted stock inducement with target value of approximately $3,350,000.","Additional relocation benefits of $800,000 are included in the amendment.","Amendment effective August 15, 2022; all other terms of original employment agreement unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348182,"accession_number":"0001077183-22-000132","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeoGenomics Q2 revenue $125M (+3%), net loss $35M; appoints Chris Smith CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $125M (+3% YoY); Clinical $106M (+4%), Pharma $19M (-4%). Net loss $35M vs $76M income (incl $97M Inivata gain).","Adjusted EBITDA negative $16M vs positive $5M in Q2 2021; adjusted net loss $20M vs $1M.","Chris Smith appointed CEO effective Aug 15; Vishal Sikri named President, Pharma Services in May.","Cash and securities $466M; company launched enterprise-wide performance improvement plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":242241000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348181,"accession_number":"0001077183-22-000124","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics appoints Chris Smith as CEO effective Aug 15, 2022; Tetrault resumes Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Smith, former CEO of Ortho Clinical Diagnostics, appointed CEO effective August 15, 2022.","Base salary $1M/year, target annual bonus 100% of salary, inducement awards ~$8.5M (RSUs and options).","Interim CEO Lynn Tetrault steps down and resumes role as independent Chair of the Board.","Smith led Ortho Clinical through its IPO ($1.45B) and Quidel merger; previously CEO of Cochlear (2015-2018).","Relocation benefits up to $400K; severance: 1x salary+bonus (non-CIC) or 3x salary+bonus (CIC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348180,"accession_number":"0001077183-22-000120","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K/A","filed_at":"2022-07-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NeoGenomics subsidiary settles with former CEO Clive Morris for £607,500 in termination payments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Settlement includes £202,500 payment in lieu of notice, £303,750 retention cash bonus component, and £101,250 pro-rated MIP bonus.","Additional payment for accrued vacation and legal fees up to £2,000 plus VAT.","Dr. Morris served as CEO of Inivata Limited, a wholly owned NeoGenomics subsidiary; employment terminated June 30, 2022.","Agreement includes full release of claims, confidentiality, and non-disparagement obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364867,"accession_number":"0001077183-22-000095","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeoGenomics say-on-pay fails at 2022 annual meeting; directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Say-on-pay received 30.6% for vs 68.9% against (advisory, non-binding).","Director Michael A. Kelly received 57.9M for, 39.1M withheld (40%).","Stockholders approved third amendment of employee stock purchase plan (99.6% for).","Ratification of independent auditor received 99.8% for (106.0M shares).","106.3M shares present (85.6% of outstanding) at June 2, 2022 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364866,"accession_number":"0001077183-22-000085","cik":1077183,"company_name":"NEOGENOMICS INC","ticker":"NEO","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NeoGenomics appoints Lynn Tetrault as Interim CEO; Chief Strategy Officer departing May 27","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lynn Tetrault named Chair of the Board and Interim CEO, effective May 12, 2022; no compensation change.","Company disbands Interim Office of the CEO; Tetrault previously served as Executive Chair since March.","Board's external search for permanent CEO is 'on track' per Lead Independent Director Michael Kelly.","Chief Strategy and Corporate Development Officer Douglas Brown leaves May 27 to pursue other interests.","CFO William Bonello and Chief Culture Officer Jennifer Balliet remain in their roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1246126764.9514563,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-16T23:59:59+00:00|364866"}